Please wait a minute...
Journal of ZheJiang University(Medical Science)  2016, Vol. 45 Issue (6): 581-586    DOI: 10.3785/j.issn.1008-9292.2016.11.04
    
Effects of icariin total flavonoids capsule on bone mineral density and bone histomorphometry in growing rats
GAO Yuhai, YANG Fangfang, XI Huirong, LI Wenyuan, ZHEN Ping, CHEN Keming
Institute of Orthopaedics Center, Lanzhou General Hospital of PLA, Lanzhou 730050, China
Download:   PDF(1130KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To investigate the effect of icariin total flavonoids capsules (ITFC) on bone mineral density (BMD) and bone histomorphometry in growing rats and its anti-osteoporosis mechanism. Methods: Thirty female SD rats were randomly divided into 3 groups:normal control group, ITFC-1 group and ITFC-2 group. Rats in ITFC-1 group and ITFC-2 group were fed with 50 mg·kg-1·d-1 or 100 mg·kg-1·d-1 ITFC, respectively, and those in normal control group were fed with equal volume of distilled water. The whole body BMD was measured after 4, 8 and 12 weeks, and BMDs of the right femur and lumbar vertebrae were measured after 12 weeks. The serum levels of tartaric acid phosphatase 5b (TRACP 5b) and bone alkaline phosphatase (BALP) were measured by ELISA. Bone morphometry was performed on the right tibia. Results: There were no significant differences in the body weight increase between normal control group and two ITFC groups (all P>0.05). There were also no significant differences in whole body BMDs after 4 and 8 weeks between normal control group and ITFC groups (all P>0.05). After 12 weeks, the whole body BMD, BMD of bone in vitro, serum BALP level and trabecular area in ITFC-1 group and ITFC-2 group were significantly higher, trabecular separation was significantly lower than that in normal control group (all P<0.05); and the trabecular width and the number in ITFC-2 group were also significantly higher, and serum TRACP 5b level was significantly lower than that in normal control group (all P<0.05). The BMD of bone in vitro, serum BALP level, trabecular number and area in ITFC-2 group were significantly higher, and serum TRACP 5b level was significantly lower than that in ITFC-1 group (all P<0.05). Conclusion: ITFC can prevent osteoporosis by increasing bone density and bone formation, decreasing bone resorption and improving microstructure of bone.



Key wordsFlavones/administration &dosage      Icariin/therapeutic use      Osteoporosis/traditional Chinese drug therapy      Bone and bones/anatomy &histology      Disease models, animal      Bone density     
Received: 08 August 2016     
CLC:  R68  
  R285  
Cite this article:

GAO Yuhai, YANG Fangfang, XI Huirong, LI Wenyuan, ZHEN Ping, CHEN Keming. Effects of icariin total flavonoids capsule on bone mineral density and bone histomorphometry in growing rats. Journal of ZheJiang University(Medical Science), 2016, 45(6): 581-586.

URL:

http://www.zjujournals.com/xueshu/med/10.3785/j.issn.1008-9292.2016.11.04     OR     http://www.zjujournals.com/xueshu/med/Y2016/V45/I6/581


淫羊藿总黄酮胶囊对生长期大鼠骨密度和骨形态计量学的影响

目的:研究淫羊藿总黄酮胶囊(ITFC)对生长期大鼠峰值骨密度和骨形态计量学的影响,探索其抗骨质疏松的作用机制。方法:30只雌性SD大鼠按体质量随机分为正常对照组、ITFC-1组及ITFC-2组。其中,ITFC-1组和ITFC-2组分别以50 mg·kg-1·d-1 ITFC和100 mg·kg-1·d-1ITFC灌胃,正常对照组灌服等体积蒸馏水。在灌胃后4、8、12周测定全身骨密度。12周后处死大鼠检测右侧股骨和腰椎骨骨密度;ELISA法检测血清抗酒石酸酸性磷酸酶5b(TRACP 5b)和骨碱性磷酸酶(BALP)水平;右侧胫骨进行骨形态计量学分析。结果:与正常对照组比较,ITFC-1组和ITFC-2组大鼠体质量增加减少,但差异无统计学意义(均P>0.05)。4周和8周时,ITFC-1组和ITFC-2组全身骨密度均有所提高,但与正常对照组差异无统计学意义(均P>0.05)。12周时,ITFC-1组和ITFC-2组大鼠全身骨密度、离体骨密度及血清BALP和骨小梁面积百分比均高于正常对照组(均P<0.05),骨小梁分离度均低于正常对照组(均P<0.05);ITFC-2组大鼠骨小梁宽度和数量均高于正常对照组,血清TRACP 5b低于正常对照组(均P<0.05);ITFC-2组大鼠离体骨密度、血清BALP、骨小梁数量和面积百分比均高于ITFC-1组,骨小梁分离度和血清TRACP 5b均低于ITFC-1组(均P<0.05)。结论:ITFC有可能通过提高骨密度、增加骨形成、降低骨吸收及改善骨组织微结构来预防老年骨质疏松的发生。


关键词: 黄酮类/投药和剂量,  淫羊藿甙/治疗应用,  骨质疏松/中药疗法,  骨和骨组织/解剖学和组织学,  疾病模型,动物,  骨密度 
[[1]]   NANES M S, KALLEN C B. Osteoporosis[J]. Semin Nucl Med, 2014, 44(6):439-450.
[[2]]   COSMAN F, DE BEUR S J, LEBOFF M S, et al. Erratum to:clinician's guide to prevention and treatment of osteoporosis[J]. Osteoporos Int, 2015, 26(7):2045-2047.
[[3]]   KARNIK A A, Feldt J M V. Osteoporosis in the elderly[J]. La Presse Médicale, 2016, 35(10 Pt 2):1547-1556.
[[4]]   GAUTAM A K, BHARGAVAN B, TYAGI A M, et al. Differential effects of formononetin and cladrin on osteoblast function, peak bone mass achievement and bioavailability in rats[J]. J Nutr Biochem, 2011, 22(4):318-327.
[[5]]   李叶丽,王颖婉,李意奇,等. 淫羊藿苷通过降低醛固酮水平减轻自发性高血压大鼠肾间质纤维化[J]. 中国药理学通报,2014,30(4):519-522. LI Yeli, WANG Yingwan, LI Yiqi, et al. Icariin attenuates renal interstitial fibrosis by reducing aldosterone in SHR[J]. Chinese Pharmacological Bulletin, 2014, 30(4):519-522.(in Chinese)
[[6]]   SETCHELL K D, LYDEKING-OLSEN E. Dietary phytoestrogens and their effect on bone:evidence from in vitro and in vivo, human observational, and dietary intervention studies.[J]. Am J Clin Nutr, 2003, 78(3 Suppl):593S-609S.
[[7]]   LI Z, PENG S, PAN H, et al. Microarchitecture and nanomechanical properties of trabecular bone after strontium administration in osteoporotic goats[J]. Biol Trace Elem Res, 2012, 145(1):39-46.
[[8]]   中国科学院中国植物志编辑委员会.中国植物志[M].北京:科学出版社,2004:296. Chinese Academy of Sciences. Flora of China[M]. Beijing:Science Press, 2014:296. (in Chinese)
[[9]]   赵文昌,宋丽军,温凯航,等. 淫羊藿抗骨质疏松症的研究进展[J]. 中国医药导报,2012,9(25):20-22. ZHAO Wenchang, SONG Lijun, WEN Kaihang, et al. Research progress of Longspur Epimedium for anti-osteoporosis[J]. China Medical Herald, 2012, 9(25):20-22. (in Chinese)
[[10]]   CUMMINGS S R, BATES D, BLACK D M. Clinical use of bone densitometry[J]. JAMA, 2002, 288(15):1889-1897.
[1] QU Tao, ZHENG Ping, YANG Chengwei, LAN Xu, ZHANG Tao, LIU Hua, WANG Shiyong. Effects of Danshensu on bone formation in ovariectomized rats[J]. Journal of ZheJiang University(Medical Science), 2016, 45(6): 587-591.
[2] ZHOU Yanfeng, GAO Yuhai, ZHEN Ping, CHEN Keming. Effects of 1.8 mT sinusoidal alternating electromagnetic fields of different frequencies on bone biomechanics of young rats[J]. Journal of ZheJiang University(Medical Science), 2016, 45(6): 561-567.
[3] WENG Xiu-Mei, PAN Jian-Ping. Bone alkaline phosphatase and N-MID osteocalcin in monitoring of osteoporosis treatment with recombinant human parathyroid hormone 1-34[J]. Journal of ZheJiang University(Medical Science), 2013, 42(5): 578-582.